Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies
复制标题
DOI：
10.1001/archotol.131.8.707
复制
发表时间：
2005-08-01
影响因子：
--
通讯作者：
Sasaki, CT
中科院分区：
文献类型：
--
作者：
Weinberger, PM;Yu, ZW;Sasaki, CT
目的：检测c-Met、c-Erb-b2(HER2/neu)和表皮生长因子(EGFR)在12例脊索瘤中的表达。设计：利用多肿瘤组织芯片和Spearman等级相关检验对档案组织的蛋白表达水平进行分析。地点：三级医疗机构。对象：我们收集了1986年至2003年耶鲁-纽黑文医院收治的12例脊索瘤患者的队列，并将其与来自17种实体组织肿瘤类型的51例其他肿瘤以及每个部位的健康组织标本进行比较。主要观察指标：c-Met、HER2/neu和EGFR的表达。结果：大多数脊索瘤显示EGFR和c-Met的强表达，而HER2/neu则有不同程度的表达。此外，我们还注意到EGFR和c-Met的表达有很强的相关性，尤其是在原发性脊索瘤中(P=0.006)。结论：脊索瘤和许多其他实体组织肿瘤一样，表达HER2/neu、EGFR和肝细胞生长因子/分散因子受体c-Met。大多数脊索瘤同时表达肝细胞生长因子/散射因子受体和EGFR。EGFR的抑制剂已经在临床上用于其他实体组织肿瘤，并代表了一种潜在可行的治疗难治性脊索瘤的实验选择。需要进一步的研究来调查这些发现。
Objective: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors.Design: Protein expression levels were analyzed by immunohistochemical analysis from archival tissue using multitumored tissue microarray and by Spearman rank correlation test.Setting: Tertiary care facility.Subjects: We assembled the cohort of 12 chordomas from patients treated at the Yale-New Haven Hospital from 1986 to 2003 and compared them with 51 other tumors from 17 assorted solid tissue tumor types along with I sample of healthy tissue from each site.Main Outcome Measure: The expression of c-Met, HER2/neu, and EGFR.Results: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas (P=.006).Conclusions: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. Most chordomas had strong expression of both the hepatocyte growth factor/scatter factor receptor and EGFR. Inhibitors to EGFR are already in clinical use for other solid-tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma. Further studies are required to investigate these findings.